The Overdose Numbers Are Dropping. Believe the Drug Supply Got More Dangerous Anyway

Bill Kinkle had been stable for six months on a daily liquid medication that stops opioid withdrawal and cravings without producing a high — methadone — when a clinic nurse in Philadelphia turned him away for arriving seven minutes late. This, she told him, would “teach him to be on time,” Kinkle wrote later in Filter. A nurse and paramedic himself, in recovery from heroin use, Kinkle went into withdrawal that day in May 2024 and bought dope on the street to get through it. He didn’t know the supply in Philadelphia had changed. Three weeks later he was in a hospital’s highest level of round-the-clock care — the intensive care unit — with doctors telling his wife to prepare for the possibility he wouldn’t make it through the night.

A national overdose death count that’s falling for the third year running is genuinely good news, and it is also the wrong number to trust with your life right now.

That’s the tension sitting underneath this week’s data. The CDC’s latest provisional figures — current as of August 4, 2026 — show roughly 68,641 overdose deaths in the 12 months ending in February, a 12.1% drop from the year before, continuing a decline that’s now three years long and the steepest sustained fall in a decade. That number is real. It is also a national average sitting on top of a drug supply that is actively getting worse in exactly the places most people who use drugs will encounter it. What killed Bill Kinkle’s old drug supply — and is now spreading fast — wasn’t fentanyl. It was a veterinary sedative called medetomidine, and it doesn’t respond to the one drug that reverses almost every other opioid overdose.

The topline number is real, and it’s not the number that matters to you tonight

Start with what the CDC data actually says, because it’s worth taking seriously on its own terms. Early counts still being revised as more death certificates come in — what the agency calls provisional data — tracked through the National Vital Statistics System show the U.S. losing about 12,700 fewer people to overdose than it did a year earlier — a continuation of a slide that began after 2023’s peak. National reporting attributes most of the improvement to a sharp drop in deaths involving synthetic opioids other than methadone, the category that includes illicit fentanyl, alongside declines in deaths involving cocaine and methamphetamine. The medication that reverses an opioid overdose — naloxone, sold over the counter under the brand name Narcan — is more available than it’s ever been. So is awareness that fentanyl is in nearly everything.

None of that is nothing. If you’re in recovery, if you’ve lost someone, if you work a syringe service program or answer an overdose hotline, three straight years of a number going down instead of up is the first sustained relief this crisis has offered since it began climbing in the mid-2010s. It deserves to be said plainly, without the hedge that usually follows good overdose news.

But a national average erases geography and erases what’s actually in the dope on a given night in a given city. Indiana’s own data, reported alongside the national figures, shows the state’s 2024 overdose death rate fell just 0.25% from the year before — a rounding error next to the national 12% — with synthetic opioids still driving roughly 62% of deaths there. The same is true, more dangerously, in the cities where a new substance being mixed into the drug supply without buyers’ knowledge — an adulterant — has already outrun the drug that made headlines before it. The national line is going down. The line for whoever is buying dope in Philadelphia, Kensington, or increasingly the Triangle in North Carolina, right now, is not telling the same story.

What’s replacing xylazine is worse, and the standard rescue drug doesn’t touch it

You’ve probably heard of xylazine — “tranq” — the animal tranquilizer that turned up in the fentanyl supply starting around 2019 and became infamous for the deep, slow-healing wounds it causes at injection sites. What’s displacing it now is medetomidine, another non-opioid veterinary sedative, and the swap follows a pattern anyone who’s watched this crisis for a decade will recognize: prohibition didn’t remove the dangerous adulterant, it upgraded it.

The scale of the shift is stark. Nabarun Dasgupta, who directs the drug-checking lab at the University of North Carolina and has testified before Congress about the changing supply, told WUNC and North Carolina Health News that his lab has now identified 536 distinct substances across more than 23,000 drug samples submitted for testing — and that medetomidine surpassed xylazine in prevalence in early 2026. In Philadelphia, where the drug first took hold, CDC investigators found it in 72% of illicit opioid samples tested between September 2024 and January 2025, and documented 165 patients hospitalized across three health systems for a withdrawal syndrome distinct from anything fentanyl or xylazine alone produces — the body’s automatic stress-response system misfiring into severe, sustained spikes in blood pressure and heart rate, a state doctors call autonomic dysfunction. Ninety-one percent of those patients needed intensive care. Nearly a quarter needed a breathing tube.

The medical detail that should change how you respond to an overdose: naloxone reverses the opioid — the fentanyl — in a mix that includes medetomidine, restoring breathing. It does nothing for the medetomidine itself. A person can be breathing again and still be unreachable, deeply sedated, unresponsive to their name or a sternum rub, for far longer than a typical opioid reversal. Philadelphia’s health department now advises responders to judge an overdose by whether someone is breathing, not whether they’re conscious, and to stay with a person, monitoring breathing, well past the point a fentanyl-only reversal would normally end. Withdrawal is its own emergency: symptoms can start within four to six hours of last use and escalate — vomiting that won’t stop, chest pain, delirium — in a way standard opioid-withdrawal medications don’t touch.

The medical detail that should change how you respond to an overdose: naloxone reverses the opioid — the fentanyl — in a mix that includes medetomidine, restoring breathing.

Elyse Powell, who directs the North Carolina Harm Reduction Coalition, described the pace of change to WUNC bluntly: “It’s getting really mucky and messy, and things are turning over really quickly.” Her organization, which reaches more than 5,000 people a year, is watching medetomidine test strips price out of reach for programs already stretched thin — about $200 for 100 strips, versus roughly $35 for fentanyl strips.

Every time the government schedules the last drug, a scarier one shows up

This isn’t the first time a crackdown on one substance has pushed the supply toward something worse, and the pattern has a name among the people who track it: whack-a-mole. Pennsylvania classified xylazine as a controlled substance in May 2024. Medetomidine’s share of the Philadelphia supply began climbing within months of that scheduling and now dominates it — a timeline Kinkle called out directly in his Filter essay: “Prohibition made xylazine less available, at least short-term, but in typical fashion it ushered in a more potent substitute.” Powell used almost the same language for the legal response chasing medetomidine now: “So we’re just sort of playing this legal whack-a-mole.”

The country has run this experiment before, on a longer arc. In 1988, Congress banned any federal money for needle exchange programs, over the objections of public health officials who’d already shown clean syringes cut HIV transmission without increasing drug use. The ban held, with brief exceptions, for nearly three decades — lifted for a year in 2009, reinstated in 2012, and not meaningfully undone until a Republican-authored provision, backed by Mitch McConnell and driven by an HIV outbreak tied to injection drug use in rural Indiana, made it into a 2016 spending bill. It took an outbreak nobody could ignore to undo a policy that had been quietly costing lives for years. The lesson wasn’t that harm reduction eventually won the argument. It was that funding fights move in slow motion while people using drugs absorb the cost in real time.

The chemistry side of the pattern has its own history. When the DEA and China moved in 2019 to schedule fentanyl and its analogues as a class, manufacturers didn’t stop — they moved to nitazenes and other novel synthetic opioids never before seen on the street, substances so new that routine toxicology screens still miss them. Scheduling xylazine in Pennsylvania produced the same shape of response in under a year. The people designing what goes into a bag of dope have always been faster than the agencies trying to write a law around the last thing they made.

The government publishing the good news pulled the funding that tracks the bad news

Here’s where this stops being just a drug-chemistry story and becomes a funding story, and it’s the part that should make you angriest. On April 24, 2026, SAMHSA issued guidance — reported first by STAT News — barring its grant recipients from using federal money to buy fentanyl, xylazine, or medetomidine test strips for public distribution, along with sterile syringes, pipes, and overdose hotlines. The agency called it a “clear shift away from harm reduction and practices that facilitate illicit drug use.” Programs can still use federal dollars for naloxone. Law enforcement, medical staff, and public health officials can still buy test strips for their own professional use. Handing a strip to the person about to use the drug — the person best positioned to act on what it tells them — is now off-limits for federally funded programs.

The timing lands exactly wrong. Test strips are how programs like Powell’s caught medetomidine’s rise in the first place — North Carolina Health News reported in June that harm reduction organizations are now caught between that SAMHSA guidance and the White House’s own 2026 National Drug Control Strategy, which separately calls test strips an important overdose-prevention tool. One federal office is funding the tool. Another is defunding it. The programs are the ones left improvising, which is a nicer way of saying: left guessing.

The programs are the ones left improvising, which is a nicer way of saying: left guessing.

The dollar figures behind that guessing are not small. STAT News reported the test-strip and syringe restrictions arrived on top of roughly $1.7 billion in previously committed block-grant funding and $350 million in addiction-prevention money already cancelled since the start of the administration. One program cited in that reporting learned it would lose a $400,000 federal grant that had funded distribution of more than 48,000 fentanyl test strips in a single quarter. Stephen Taylor, president of the American Society of Addiction Medicine, said his organization would “engage with federal partners to ensure that national policies reflect evidence-based practices” — the kind of careful, diplomatic sentence professional associations reach for when they mean a policy is going to hurt people and they’re trying to stay in the room long enough to argue about it.

What actually still works, and what to do with it

If you’re using or you’re around someone who is, here’s what hasn’t changed and what has. Naloxone is still free in most places, still legal to carry, and still the single most important thing you can have on you — it will still reverse the fentanyl in a mix, which is most of what’s killing people. What’s changed is what happens after: don’t assume breathing means safe. If someone’s breathing is restored but they’re still unresponsive, stay. Put them in the recovery position — on their side, so they can’t choke — and keep checking their breathing, because a medetomidine-heavy dose can keep a person sedated for hours after naloxone has done everything it can do. If you’re in withdrawal and it doesn’t feel like withdrawal you’ve had before — chest pain, vomiting that won’t quit, a heart that won’t slow down — that’s not a night to white-knuckle at home. That’s an ER, the way Kinkle eventually went, even knowing what emergency rooms can be like for someone they’ve already decided is a drug user. You’ve been dismissed by a nurse before. Go anyway. The alternative is worse.

One more thing that’s still true and still free: fentanyl test strips remain legal in most states even where federal grant money can no longer buy them for you, and community-based harm reduction programs — the ones not entirely dependent on that federal funding stream — are still handing them out. Ask. It’s a five-second test that could tell you the difference between an ordinary bad night and the kind of three weeks Bill Kinkle spent in a burn ICU getting skin grafts he’s still recovering from.

Kinkle is alive. He’s back to advocating, back to co-hosting a podcast for healthcare workers navigating their own substance use in a field that treats it as a fireable offense rather than a health condition. He’s also permanently changed by what medetomidine did to his body, and he’s said plainly that he doesn’t expect to be the same man he was before 2020. The overdose curve is bending in the right direction for the first time in a decade. Whether it stays bent depends less on that topline number than on whether the next Bill Kinkle finds out what’s actually in the dope before, instead of after, three weeks in an ICU.